AirSculpt Technologies (AIRS) Q3 2026 earnings review
AirSculpt pushes its debt to 2031, but clinic volume drops
AirSculpt Technologies, the operator of minimally invasive fat-removal clinics, saw its nascent volume recovery reverse while a new loan removed its debt deadline. Procedures at clinics open a year ago fell 10% and revenue dropped 9%, even though surgeries tied to weight-loss drugs reached a tenth of all cases. Chief executive Yogi Jashnani cut the full-year outlook to match the weak quarter, which by our math leaves fourth-quarter sales down 8% from a year ago.
| Same-center case volume | 2,483 -9.6% from a year ago (+1.0% in Q2) |
|---|---|
| Revenue | $31.9M -8.7% from a year ago |
| Adjusted EBITDA | $0.4M 1.2% of revenue (8.7% a year ago) |
| Full-year outlook | Cut revenue $144–146M; Adjusted EBITDA $9–10M |
⚖️ Verdict: 🔴 Bearish
The story got worse because patient demand broke down again after two flat quarters, wiping out nearly all operating profit despite higher marketing spend. The good news: AirSculpt signed a $39 million loan due in 2031 after the quarter ended, removing the November 2027 debt maturity and the rule that forced half of any stock-sale proceeds to go to lenders.
The question now is whether the five-year loan gives AirSculpt enough breathing room to fix clinic traffic, or only saddles a shrinking business with expensive debt. Either weight-loss procedures grow fast enough to offset the ~19% drop in traditional cases by our math, or high overhead keeps cash flow negative. The loan terms in the quarterly filing and fourth-quarter case volume will tell.
🐂 Bull Case
Five-Year Loan Removes the 2027 Debt Deadline
AirSculpt's biggest near-term threat was its credit facility due in November 2027, which forced the fat-removal clinic operator to hand half of any stock-sale proceeds to its lenders. During the third quarter, the company raised $7.2 million by selling shares and paid down $7.0 million of debt, lowering gross debt to about $37.2 million.
On November 5, AirSculpt signed a new loan agreement with Blue Torch Finance that chief executive Yogi Jashnani called "a key milestone as we completed the refinance of our term loan - extending our debt maturity to 2031". The deal provides a $39.0 million term loan and an undrawn $5.0 million credit line, paying off the old loan and its fees in full.
What to watch: the interest rate and financial covenants on the Blue Torch loan in the third-quarter filing. A high interest rate or a strict profit rule could still strain cash flow while earnings are near zero.
Weight-Loss Drug Procedures Reached 10% of Cases
AirSculpt is trying to win patients who have lost weight on GLP-1 drugs — prescription weight-loss medications — by offering skin removal and body-contouring surgeries. Jashnani highlighted "expanding our GLP-1-related procedures" as a priority, and for the first time the release gave a quarterly share: about 250 procedures, or roughly 10% of all 2,483 cases.
Those surgeries helped lift revenue per case at clinics open at least a year by 2.3% to $12,865, reversing a 2.0% decline in the second quarter. However, AirSculpt still does not state how much revenue these procedures bring in or how many came from new customers rather than add-ons.
What to watch: GLP-1 procedure volume and revenue per case in the fourth quarter. A higher share alongside rising revenue per case would show that weight-loss patients are lifting average ticket prices.
🐻 Bear Case
Procedure Volume Fell Back Into a Slump
AirSculpt had stabilized procedure count at clinics open a year ago at 1.1% growth in the first quarter and 1.0% in the second. "While our third quarter results were below expectations, we identified the key drivers and are addressing them with a sense of urgency," Jashnani said. Same-center volume dropped 9.6% to 2,483 cases, even though the year-ago quarter had already fallen 20.5%.
- Same-center revenue: down 7.6% from a year ago by our math, after a 1.0% dip in Q2
- Cases outside GLP-1 procedures: down about 19% from a year ago by our math
- Full-year revenue outlook: cut by $7 million at the middle of the range to $144–146 million
That drop shows the extra marketing money spent earlier this year did not bring in enough patients to offset falling demand for standard fat-removal procedures. Jashnani cut the full-year outlook to "reflect our third quarter performance continuing through year-end", which by our math leaves fourth-quarter revenue down 8.0% from a year ago.
What to watch: same-center case volume in the fourth quarter against a base of 2,345 cases. Another drop on top of last year's 18.5% decline would show that patient demand is still shrinking.
Higher Overhead Wiped Out Most Operating Profit
Last quarter AirSculpt cut its full-year profit outlook to put an extra $5 million into advertising, saying the spending would build the brand and bring patients into clinics later. In the third quarter, selling, general and administrative expenses — advertising and corporate overhead — rose to $20.3 million from $19.5 million a year ago, even as revenue fell 8.7%.
Cost of service — the direct cost of surgeons, nurses and clinic rooms — fell by 2.1 percentage points of revenue to 40.4%, lifting gross margin to 59.6%. But advertising and overhead jumped by 7.6 percentage points of revenue to 63.4%. That pushed Adjusted EBITDA — profit before interest, taxes, depreciation and one-offs — down from $3.0 million to $0.4 million, or 1.2% of sales.
What to watch: selling, general and administrative expenses as a share of revenue in the fourth quarter. A reading above 60% would show that marketing and overhead costs remain too high for the current number of procedures.
The Smaller Net Loss Is an Accounting Mirage
AirSculpt's third-quarter highlights note that the net loss narrowed by $2.3 million from a year ago, to $7.2 million. That improvement is an accounting quirk from a one-off charge last year, when the company wrote off $7.1 million for a software project and the closure of its London clinic.
Without that write-off, pre-tax loss worsened by $1.4 million by our math, and AirSculpt recorded $1.8 million of income tax expense against a $1.6 million tax benefit a year ago. Excluding one-offs, net loss more than doubled from $2.4 million ($0.04 per share) to $6.1 million ($0.08 per share), which matches the drop in procedure volume.
What to watch: one-time SOX compliance and restructuring add-backs in the fourth quarter, which reached $2.8 million over the first nine months. Continued add-backs at that pace would keep a wide gap between reported losses and Adjusted EBITDA.
Share Sales Lifted the Share Count 16%
AirSculpt paid down debt over the past year by selling new stock into the open market rather than generating cash from its clinics. In the third quarter, the surgical group raised another $7.2 million through its at-the-market stock offering program and used $7.0 million to pay down its old term loan before refinancing.
Those share sales pushed the diluted share count up 16.2% from a year ago to 72.5 million shares, up from 70.8 million in the second quarter. Each existing share now owns a smaller piece of any future recovery.
What to watch: share issuance under the at-the-market program now that the Blue Torch loan is in place. Stopping share sales would show the new credit facility gives AirSculpt enough cash to run on its own.
💲 Other KPIs
Operations burned $3.48 million of cash in the third quarter, worse than the $0.23 million outflow a year ago and the $1.24 million outflow in the second quarter. For the first nine months, operating cash flow fell to $0.56 million from $5.63 million last year as procedure volume and operating profit shrank.
Deferred revenue and patient deposits — upfront payments from patients for surgeries not yet performed — rose to $3.35 million from $3.15 million in the second quarter and $0.88 million a year ago. Because AirSculpt collects payment before surgery, this balance represents booked procedures, though it covers only about onetenth of a quarter's sales.
By our math, carrying debt of $36.66 million (about $37.2 million gross) minus $15.18 million of cash left $21.48 million of net debt at September 30, down from $24.74 million in the second quarter and $47.60 million at year-end 2025. After quarter-end, the company replaced the old debt with a $39.0 million term loan.
🔮 Guidance
Cut. The middle of the range dropped by $6 million from the prior $151 million low-end target, pointing to a 4.5% full-year decline. By our math, that leaves $30.8 million for the fourth quarter, down 8.0% from a year ago (or up 1.8% at clinics open a year ago, since the closed London clinic sits in last year's total). It is the second reduction in two quarters: -$3M, then -$6M.
Cut. The middle of the range dropped by $3.5 million, putting full-year Adjusted EBITDA down 24% from last year's restated $12.5 million. By our math, that leaves $0.86 million for the fourth quarter (a 2.8% margin), compared with a $0.13 million loss in the fourth quarter of 2025. This is the second cut in two quarters: -$3.0M in Q2, then -$3.5M in Q3.
❓ Key Questions
What are the interest rate and covenants on the loan?
AirSculpt replaced its bank debt with a $39.0 million term loan from Blue Torch Finance due in 2031, but the release did not disclose the interest rate, fees or financial covenants. With annual Adjusted EBITDA down to $9–10 million, borrowing costs matter.
What caused same-center volume to drop 9.6%?
Chief executive Yogi Jashnani said the company "identified the key drivers" behind the third-quarter shortfall and is addressing them, without naming what they were in the release. Investors need to know whether leads fell, consultations failed to convert, or patients balked at financing.
Did the AlloClae injectable pilot start treating patients?
Last quarter management said its first clinics would begin treating patients with AlloClae — an injectable fat matrix — during the third quarter. The earnings release did not mention AlloClae once.
How much revenue came from GLP-1 procedures?
AirSculpt disclosed that GLP-1-related procedures reached about 250 cases, or 10% of total volume, in the third quarter. It still has not disclosed the dollar revenue from those cases or how many were standalone patients versus add-ons.